Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The associated myeloid neoplasm, not the mast cells, now causes most deaths in SM-AHN.
Whether KIT inhibitors improve survival has not been shown in a randomised trial.
Thrombocytopenic patients cannot receive avapritinib safely.
Transplant outcomes rest on small retrospective series.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Advanced systemic mastocytosis
Overall response rate 75 percent and complete remission rate 36 percent in 53 evaluable patients with advanced systemic mastocytosis; maximum tolerated dose not reached; recommended dose 200 mg daily; approved June 2021.
A milestone in how this cancer is treated.
Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis